Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 47 clinical trials
Dasatinib Holiday for Improved Tolerability

Inhibitors (2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))

nilotinib
hydroxyurea
ponatinib
dasatinib
bosutinib
  • 11 views
  • 05 Feb, 2021
  • 80 locations
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete

leukemia
remission
dasatinib
  • 7 views
  • 08 Nov, 2020
  • 1 location
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic myeloid leukemia

  • 38 views
  • 11 May, 2021
  • 442 locations
Treatment Modification Based on Early Assessment of CML Patients

TKI (as nilotinib, dasatinib). The investigators will follow on lab and clinical outcomes.

tyrosine
nilotinib
dasatinib
philadelphia chromosome positive chronic myelogenous leukemia
leukemia
  • 5 views
  • 08 Nov, 2020
  • 1 location
Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

associated with imatinib or dasatinib has acceptable tolerability in elderly patients. To determine whether this association can increase the rate and quality of referrals to the results of the

  • 1 views
  • 28 Jan, 2021
  • 1 location
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)

open at any times later on. Authorized TKIs are imatinib, nilotinib, dasatinib, bosutinib and ponatinib. For all options the treatment duration is for a minimum of 12 months and will be

  • 11 views
  • 24 Jan, 2021
  • 24 locations
Study in Patients With Chronic Leukemia Where Previous Therapy Failed and Who Will be Treated With Ponatinib as Second Line Therapy

This study will include patients suffering from chronic myeloid leukemia (CP-CML), who were treated with tyrosine kinase inhibitor (TKI, a substance that blocks the action of enzymes) in a previous therapy but which has not been effective. Patients will be treated with Ponatinib 30 mg in in this study. The …

  • 0 views
  • 15 May, 2021
  • 10 locations
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

The purpose of this multicenter randomized study is to compare efficacy and safety of dasatinib 50 mg once daily and dasatinib 100 mg once daily in patients with early chronic phase (CP) chronic

tyrosine
leukemia
hydroxyurea
kinase inhibitor
cytarabine
  • 8 views
  • 23 Jan, 2021
  • 4 locations
A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL

refractory to or are intolerant of TKIs, and of ABL001+Nilotinib, ABL001+Imatinib and ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.

tyrosine
imatinib
dasatinib
nilotinib
  • 106 views
  • 22 May, 2021
  • 18 locations
Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

This study will enroll CML patients who have failed a first TKI stopping attempt. After failure and at least a year of TKI treatment, patients will proceed to dasatinib treatment for another 2

  • 18 views
  • 22 Jan, 2021
  • 22 locations